Antiphospholipid syndrome and IgA anti-beta2-glycoprotein I antibodies: when Cinderella becomes a princess

被引：24

作者：

Perez, D. ^{[1
,2
]}

Tincani, A. ^{[3
]}

Serrano, M. ^{[1
]}

Shoenfeld, Y. ^{[2
]}

Serrano, A. ^{[1
]}

机构：

[1] Hosp Univ 12 Octubre, Dept Immunol, Avda Andalucia S-N, Madrid 28041, Spain

[2] Sheba Med Ctr, Zabludowicz Ctr Autoimmune Dis, Tel Aviv, Israel

[3] Spedali Civili Brescia, Rheumatol & Clin Immunol Dept, Brescia, Italy

来源：

LUPUS | 2018年 / 27卷 / 02期

关键词：

Anti-B2GPI; APS; thrombosis; antiphospholipid antibodies; laboratory criteria; IgA; SYSTEMIC-LUPUS-ERYTHEMATOSUS;

D O I：

10.1177/0961203317738227

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

IgA anti-beta2-glycoprotein I (IgA-aB2GPI) antibodies are currently not included as a laboratory criterion of antiphospholipid syndrome (APS). In the 13th International Congress on Antiphospholipid Antibodies, Galveston, TX, (USA) in 2010, these antibodies were accepted as an APS laboratory criterion in patients who had clinical manifestations of APS but were negative for consensus antiphospholipid antibodies (aPL) (IgG and IgM isotypes). Consequently, individuals with thrombotic events who are negative for consensus aPL may be undiagnosed for APS. The most recent publications have confirmed that IgA-aB2GPI antibodies are a risk factor for thrombotic events. In this viewpoint, we propose that IgA-aB2GPI antibodies should be included as an APS consensus criterion and that we have to help Cinderella become a princess.

引用

页码：177 / 178

页数：2

共 10 条

[1] Antiphospholipid antibodies as non-traditional risk factors in atherosclerosis based cardiovascular diseases without overt autoimmunity. A critical updated review [J].

Artenjak, Andrej ;

Lakota, Katja ;

Frank, Mojca ;

Cucnik, Sasa ;

Rozman, Blaz ;

Bozic, Borut ;

Shoenfeld, Yehuda ;

Sodin-Semrl, Snezna .

AUTOIMMUNITY REVIEWS, 2012, 11 (12) :873-882

[2] Primary Thrombosis Prophylaxis in Antiphospholipid Antibody-Positive Patients: Where Do We Stand? [J].

Barbhaiya, Medha ;

Erkan, Doruk .

CURRENT RHEUMATOLOGY REPORTS, 2011, 13 (01) :59-69

[3] Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients [J].

Cervera, R. ;

Serrano, R. ;

Pons-Estel, G. J. ;

Ceberio-Hualde, L. ;

Shoenfeld, Y. ;

de Ramon, E. ;

Buonaiuto, V. ;

Jacobsen, S. ;

Zeher, M. M. ;

Tarr, T. ;

Tincani, A. ;

Taglietti, M. ;

Theodossiades, G. ;

Nomikou, E. ;

Galeazzi, M. ;

Bellisai, F. ;

Meroni, P. L. ;

Derksen, R. H. W. M. ;

de Groot, P. G. D. ;

Baleva, M. ;

Mosca, M. ;

Bombardieri, S. ;

Houssiau, F. ;

Gris, J-C ;

Quere, I. ;

Hachulla, E. ;

Vasconcelos, C. ;

Fernandez-Nebro, A. ;

Haro, M. ;

Amoura, Z. ;

Miyara, M. ;

Tektonidou, M. ;

Espinosa, G. ;

Bertolaccini, M. L. ;

Khamashta, M. A. .

ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 (06) :1011-1018

[4] International Consensus Guidelines on Anticardiolipin and Anti-β2-Glycoprotein I Testing: Report From the 13th International Congress on Antiphospholipid Antibodies [J].

Lakos, Gabriella ;

Favaloro, Emmanuel J. ;

Harris, E. Nigel ;

Meroni, Pier Luigi ;

Tincani, Angela ;

Wong, Richard C. ;

Pierangeli, Silvia S. .

ARTHRITIS AND RHEUMATISM, 2012, 64 (01) :1-10

[5] Heterogeneity between Diagnostic Tests for IgA anti-Beta2 Glycoprotein I: Explaining the Controversy in Studies of Association with Vascular Pathology [J].

Martinez-Flores, Jose A. ;

Serrano, Manuel ;

Alfaro, Javier ;

Mora, Sergio ;

Paz-Artal, Estela ;

Morales, Jose M. ;

Serrano, Antonio .

ANALYTICAL CHEMISTRY, 2013, 85 (24) :12093-12098

[6] Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: a nationwide prospective study [J].

Mustonen, P. ;

Lehtonen, K. V. ;

Javela, K. ;

Puurunen, M. .

LUPUS, 2014, 23 (14) :1468-1476

[7] Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus [J].

Petri, Michelle ;

Orbai, Ana-Maria ;

Alarcon, Graciela S. ;

Gordon, Caroline ;

Merrill, Joan T. ;

Fortin, Paul R. ;

Bruce, Ian N. ;

Isenberg, David ;

Wallace, Daniel J. ;

Nived, Ola ;

Sturfelt, Gunnar ;

Ramsey-Goldman, Rosalind ;

Bae, Sang-Cheol ;

Hanly, John G. ;

Sanchez-Guerrero, Jorge ;

Clarke, Ann ;

Aranow, Cynthia ;

Manzi, Susan ;

Urowitz, Murray ;

Gladman, Dafna ;

Kalunian, Kenneth ;

Costner, Melissa ;

Werth, Victoria P. ;

Zoma, Asad ;

Bernatsky, Sasha ;

Ruiz-Irastorza, Guillermo ;

Khamashta, Munther A. ;

Jacobsen, Soren ;

Buyon, Jill P. ;

Maddison, Peter ;

Dooley, Mary Anne ;

van vollenhoven, Ronald F. ;

Ginzler, Ellen ;

Stoll, Thomas ;

Peschken, Christine ;

Jorizzo, Joseph L. ;

Callen, Jeffrey P. ;

Lim, S. Sam ;

Fessler, Barri J. ;

Inanc, Murat ;

Kamen, Diane L. ;

Rahman, Anisur ;

Steinsson, Kristjan ;

Franks, Andrew G., Jr. ;

Sigler, Lisa ;

Hameed, Suhail ;

Fang, Hong ;

Ngoc Pham ;

Brey, Robin ;

Weisman, Michael H. .

ARTHRITIS AND RHEUMATISM, 2012, 64 (08) :2677-2686

[8]

PIERANGELI SS, 1995, THROMB HAEMOSTASIS, V74, P1361

[9] Incidence of thromboembolic events in asymptomatic carriers of IgA anti β2 glycoprotein-I antibodies [J].

Tortosa, Carlos ;

Cabrera-Marante, Oscar ;

Serrano, Manuel ;

Martinez-Flores, Jose A. ;

Perez, Dolores ;

Lora, David ;

Morillas, Luis ;

Paz-Artal, Estela ;

Morales, Jose M. ;

Pleguezuelo, Daniel ;

Serrano, Antonio .

PLOS ONE, 2017, 12 (07)

[10]

Tsutsumi A, 1998, J RHEUMATOL, V25, P74

← 1 →